Get the Stockscreener App
8.20
6.43%
0.50
After Hours:
8.23
0.03
+0.37%
Immunitybio Inc stock is traded at $8.20, with a volume of 16.13M.
It is up +6.43% in the last 24 hours and down -3.25% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.70
Open:
$7.66
24h Volume:
16.13M
Relative Volume:
0.43
Market Cap:
$8.47B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-21.04
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
+12.26%
1M Performance:
-3.25%
6M Performance:
+234.49%
1Y Performance:
+231.78%
1-Day Range:
$7.65
$8.35
1-Week Range:
$7.12
$8.35
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.20 | 7.95B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
439.18 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.41 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
834.45 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.94 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
318.07 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - GlobeNewswire
ImmunityBio Inc stock (US45258J1025): Is its immunotherapy pipeline strong enough to unlock new upsi - AD HOC NEWS
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential - GlobeNewswire
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with - GlobeNewswire
ImmunityBio, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsIBRX - Lelezard
ImmunityBio Inc stock (US45258J1025): Is its cancer immunotherapy platform strong enough to unlock n - AD HOC NEWS
ImmunityBio's Legal Deadline and Record Revenue Collide - AD HOC NEWS
IBRX Founder Backs Trump’s Psychedelic Push In ‘Transforming’ Health Policy — Flags New Anktiva Breast Cancer Risk Data - Stocktwits
ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - The Globe and Mail
Lobbying Update: $60,000 of IMMUNITYBIO INC. lobbying was just disclosed - Quiver Quantitative
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Concorde International Group Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ImmunityBio, Inc. (IBRX) posts strong preliminary Q1 sales on ANKTIVA momentum - MSN
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit - The Globe and Mail
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securi - GuruFocus
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - PR Newswire
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C. - The Spec
Deadline to Lead in Securities Class Action Against ImmunityBio - The National Law Review
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights - The Daily Tribune News
Deadline to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026Contact Kaplan Fox - The Globe and Mail
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit Investors With Losses ... - Bluefield Daily Telegraph
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class - GlobeNewswire
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — Hagens Berman - Morningstar
Reframing ImmunityBio: The Long-Term Platform Opportunity Beyond Anktiva (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio (IBRX) Global Expansion Bolsters 266% Jump This Year - Yahoo Finance
2026-04-17 | IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:IBRX | Press Release - Stockhouse
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
IBRX Stock Price, Quote & Chart | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure ... - Caledonian Record
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ImmunityBio, Inc. (IBRX) Facing Securities Class Action - GlobeNewswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
ImmunityBio (IBRX) price target increased by 15.63% to 15.10 - MSN
IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - Barchart.com
IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation RisksImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt – Company Announcement - Financial Times
IBRX INVESTOR ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
ImmunityBio, Inc. (NASDAQ:IBRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
IMMUNITYBIO, INC. (IBRX) - MSN
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Subst - GuruFocus
Robbins LLP Urges ImmunityBio Shareholders to Join Class Action - National Today
ImmunityBio Investors Face Deadline for Lead Plaintiff Role - National Today
Deadline Approaching for ImmunityBio Investors to Seek Lead Plaintiff Role - National Today
Robbins LLP Urges IBRX Stockholders Who Lost Money Investing in ImmunityBio, Inc. to Contact the Firm for Information About Leading the Class Action - Morningstar
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):